两阶段假体乳房重建与脱细胞真皮基质辅助即刻一阶段假体乳房重建的比较:一项开放标签、4期、多中心、随机对照试验
该研究在荷兰8家医院开展开放标签随机对照试验,纳入142例拟行保留皮肤乳房切除并即刻假体乳房重建的乳腺癌或乳腺癌相关基因突变女性,比较脱细胞真皮基质(ADM)辅助一阶段与两阶段假体乳房重建的安全性。ADM辅助一阶段重建每侧乳房手术并发症、再手术及假体或ADM取出风险均显著高于两阶段重建,严重(3级)不良事件更常见。作者认为该术式应非常谨慎考虑。
要点
- ADM辅助一阶段重建每侧乳房手术并发症粗比值比3.81(95%CI 2.67-5.43,p<0.001),高于两阶段重建。
- ADM辅助一阶段重建再手术粗比值比3.38(95%CI 2.10-5.45,p<0.001),高于两阶段重建。
- ADM辅助一阶段重建假体、ADM或两者取出粗比值比8.80(95%CI 8.24-9.40,p<0.001),高于两阶段重建。
核心结论
- ADM辅助即刻一阶段假体乳房重建与不良事件相关,应非常谨慎考虑;患者选择、危险因素及手术与术后流程的认识有待提高。
研究设计与样本
- 开放标签、随机对照试验,在荷兰8家医院开展;2013年4月14日至2015年5月29日入组142例女性。
- 纳入年龄大于18岁、患乳腺癌或携带乳腺癌相关基因突变、拟行保留皮肤乳房切除并即刻假体乳房重建的女性。
- 电子随机化,按中心分层、每10例为一区组,分为ADM(Strattice,LifeCell,Branchburg,NJ,USA)辅助一阶段假体乳房重建组或两阶段假体乳房重建组;分析按方案进行,采用逻辑回归和广义估计方程。
- 分析纳入ADM辅助一阶段组59例(91侧乳房)和两阶段组62例(92侧乳房);试验注册于Nederlands Trial Register,注册号NTR5446。
主要发现
- ADM辅助一阶段重建每侧乳房手术并发症风险显著高于两阶段重建,粗比值比3.81(95%CI 2.67-5.43,p<0.001)。
- ADM辅助一阶段重建再手术风险显著高于两阶段重建,粗比值比3.38(95%CI 2.10-5.45,p<0.001)。
- ADM辅助一阶段重建假体、ADM或两者取出风险显著高于两阶段重建,粗比值比8.80(95%CI 8.24-9.40,p<0.001)。
- 严重(3级)不良事件在ADM辅助一阶段组为91侧乳房中26侧(29%),在两阶段组为92侧乳房中5侧(5%)。
- 轻至中度不良事件频率在两组间相似。
关键数值与推荐
- ADM辅助一阶段重建每侧乳房手术并发症粗比值比3.81(95%CI 2.67-5.43,p<0.001),对照为两阶段重建。
- ADM辅助一阶段重建再手术粗比值比3.38(95%CI 2.10-5.45,p<0.001),对照为两阶段重建。
- ADM辅助一阶段重建假体、ADM或两者取出粗比值比8.80(95%CI 8.24-9.40,p<0.001),对照为两阶段重建。
- 严重(3级)不良事件:ADM辅助一阶段组91侧乳房中26侧(29%)vs 两阶段组92侧乳房中5侧(5%)。
临床怎么用
- 作者认为ADM辅助即刻一阶段假体乳房重建与不良事件相关,应非常谨慎考虑,并需改进患者选择、危险因素及手术与术后流程的认识。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The evidence justifying the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR) is limited. We did a prospective randomised trial to compare the safety of IBBR with an ADM immediately after mastectomy with that of two-stage IBBR. METHODS: We did an open-label, randomised, controlled trial in eight hospitals in the Netherlands. Eligible women were older than 18 years with breast carcinoma or a gene mutation linked with breast cancer who intended to undergo skin-sparing mastectomy and immediate IBBR. Randomisation was done electronically, stratified per centre and in blocks of ten to achieve roughly balanced groups. Women were assigned to undergo one-stage IBBR with ADM (Strattice, LifeCell, Branchburg, NJ, USA) or two-stage IBBR. The primary endpoint was quality of life and safety was assessed by the occurrence of adverse outcomes. Analyses were done per protocol with logistic regression and generalised estimating equations. This study is registered at Nederlands Trial Register, number NTR5446. FINDINGS: 142 women were enrolled between April 14, 2013, and May 29, 2015, of whom 59 (91 breasts) in the one-stage IBBR with ADM group and 62 (92 breasts) in the two-stage IBBR group were included in analyses. One-stage IBBR with ADM was associated with significantly higher risk per breast of surgical complications (crude odds ratio 3·81, 95% CI 2·67-5·43, p<0·001), reoperation (3·38, 2·10-5·45, p<0·001), and removal of implant, ADM, or both (8·80, 8·24-9·40, p<0·001) than two-stage IBBR. Severe (grade 3) adverse events occurred in 26 (29%) of 91 breasts in the one-stage IBBR with ADM group and in five (5%) of 92 in the two-stage IBBR group. The frequency of mild to moderate adverse events was similar in the two groups. INTERPRETATION: Immediate one-stage IBBR with ADM was associated with adverse events and should be considered very carefully. Understanding of selection of patients, risk factors, and surgical and postsurgical procedures needs to be improved. FUNDING: Pink Ribbon, Nuts-Ohra, and LifeCell.
引用
- Dikmans RE, Negenborn VL, Bouman MB, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. Lancet Oncol. 2016. PMID: 28012977. doi:10.1016/S1470-2045(16)30668-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。